Nasdaq · Healthcare
Coherus Oncology, Inc. (CHRS)
As-reported financials and recent SEC filings for Coherus Oncology, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$42.2M
Net income
$168.0M
Net margin
—
Diluted EPS
$1.43
ROE
275.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M |
| Gross profit | $28.4M | $17.7M | $98.3M | $141.0M | $269.0M |
| Operating income | $-181.1M | $-199.7M | $-203.2M | $-256.9M | $-263.9M |
| Net income | $168.0M | $28.5M | $-237.9M | $-291.8M | $-287.1M |
| Diluted EPS | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-15
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →Largest Healthcare peers
Go deeper on CHRS
Search Coherus Oncology, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.